 |
 |
|
|
Articles 
Douglas G.W. Fraser, Alan R. Moody, Paul S. Morgan, Anne L. Martel, and Ian Davidson Magnetic resonance direct thrombus imaging (MRDTI) is an accurate noninvasive test for diagnosis of deep venous thrombosis, and its accuracy is maintained below the knee. Comparison of individual venous segments showed that results of MRDTI agreed strongly with findings on venography. Scanning was well tolerated, and interpretation was highly reproducible.
James D. Lewis, Alphonso Brown, A. Russell Localio, and J. Sanford Schwartz Evaluation of the colon of persons 25 to 45 years of age with otherwise asymptomatic rectal bleeding increases the life expectancy at a cost similar to that of colon cancer screening.
Sheldon Greenfield, Sherrie H. Kaplan, Richard Kahn, John Ninomiya, and John L. Griffith The findings of this study underscore the importance of designing physician profiling studies with sufficient power to account for physician-level variation (clustering) as well as patient case-mix. Studies that are not designed with sufficient numbers of physicians and patients per physician may distort differences in quality of care between physician groups.
Brief Communications
Marcus Müllner, Hugh Matthews, and Douglas G. Altman Details of methods used to adjust for confounding were frequently not reported in original research articles in 34 scientific medical journals with a high impact factor.
Academia and Clinic
Michael J. Barry Health decision aids facilitate shared decision making by helping patients and their physicians choose among reasonable clinical options. Although these aids vary in content, common denominators are the presentation of more than one reasonable strategy for a clinical management question and a description of the possible outcomes of the various options.
Reviews
C. Tom Kouroukis, George P. Browman, Rosmin Esmail, and Ralph M. Meyer For treatment of older patients with advanced-stage, aggressive-histology lymphoma who do not have significant comorbid illnesses, an anthracycline-containing regimen, such as CHOP, given in standard doses and schedule provides superior outcomes compared with other regimens.
Clinical Guidelines
U.S. Preventive Services Task Force* The U.S. Preventive Services Task Force strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk for coronary heart disease. Discussions with patients should address both the potential benefits and harms of aspirin therapy.
Michael Hayden, Michael Pignone, Christopher Phillips, and Cynthia Mulrow This systematic review supports the U.S. Preventive Services Task Force's position on aspirin chemoprevention for adults at risk for coronary heart disease.
Editorials
John M. Eisenberg The study by Greenfield and colleagues in this issue prompts us to ask whether the data that compare physician groups—and, by extension, the data that compare individual physicians, hospitals, or health plans—are fair to those being measured and useful to decision makers.
Harold C. Sox This issue marks the first of a series of articles describing the state of the art and science of disease prevention, as interpreted by the U.S. Preventive Services Task Force. Annals will publish these reports because we believe that internists should have convenient access to the best evidence about disease prevention, a core activity for most internists.
Letters Prevention of Antibiotic Resistance in Hospitals
Viral Pneumonia as a Serious Complication of Etanercept Therapy
Abuse of Epinephrine as a Stimulant
Correction: Multiple Measures of Adherence to HIV Protease Inhibitors
Correction: Guidelines for the Management of Patients with Chronic Stable Angina: Diagnosis and Risk Stratification
Roger P. Smith
Rebecca Wurtz
Tom Reynolds
Vinay Kamat
Cortney Davis
Joseph P. Catlett and Barbara M. Alving The authors discuss advances in the following areas of hematology: target-specific drugs for cancer, self-management of oral anticoagulant therapy, understanding risks for venous thromboembolism in women during pregnancy and in postmenopausal women who are undergoing hormone replacement therapy, and management of patients with sickle-cell disease. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
In this Issue
Articles
Previous Issue